In the 10-K report, Liquidia Corporation reported a net loss of $130.4 million for the year ended December 31, 2024, compared ...
Corsair Pharma is planning a Phase 1 clinical trial of its treprostinil skin patch as a treatment for pulmonary arterial hypertension (PAH).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback